Capricor Therapeutics Stock Skyrockets Over 340% On Positive Phase 3 HOPE-3 Trial Results

Core Viewpoint - Capricor Therapeutics, Inc. experienced a significant stock surge of 342.30 percent following the announcement of positive topline data from its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy [1] Group 1: Stock Performance - Capricor's shares rose by $21.77 to reach $28.13 on Wednesday, compared to a previous close of $6.36 [2] - The stock opened at $30.00 and has fluctuated between $21.50 and $40.37 during the trading day, with a trading volume of 39.80 million shares [2] - The company's 52-week stock range is between $4.30 and $40.37 [2] Group 2: Clinical Trial Results - The HOPE-3 trial demonstrated statistically significant improvements in both skeletal and cardiac function [1] - The results reinforced the durability of the findings observed in the earlier HOPE-2 studies [1]